Royalty Report: Drugs, Biotechnology, Diagnostic – Collection: 7597

License Grant

Therefore the Licensor, a University, grants an exclusive license to the Licensed Patents, and an exclusive license to the Know How, to make, have made, use, import, offer to sell and sell Licensed Products and to practice the Licensed Process(es) in the Field of Use and Territory to the Licensee
Licensee may sublicense the rights granted.

License Property

The invention relates to methods for modulating the immune function through targeting of CLIP molecules.

Invention Disclosures
CU1760C- Selective Modulation of Gamma Delta T Cells to Treat Autoimmune Diseases, HIV, and Cancer
CU1969C – Competitive inhibitors of Invariant Chain expression and/or ectopic CLIP binding
CU1971C- Use of soluble H-2M (HLA-DM) as a CLIP displacement therapy (combined with CU1969C and patents filed under CU1969C)
CU2131C- Topical HIV prevention cream/gel (provisional application was abandoned as it was covered under applications filed in CU1760C and CU1969C)
CU2253C – The use of non-specific CLIP displacing peptides to treat or prevent chronic disease mediated by infectious organisms (no patents filed yet)
CU2254C – The use of peptides derived from an infectious organism that displace CLIP in order to treat or prevent chronic conditions mediated by those very organisms (no patents filed yet)

Patent Applications
Country
Serial No
File Date
Title
lnternal ID

United States
60/886,852
01/26/2007
Methods of Modulating Immune Function Through Targeting of Invariant Chain/CD74 and Clip
CU1760C- PPA1

United States
60/906,731
03/13/2007
Immune Mechanism For The Depletion of CD4+ T Cells
CU1760H- PPA2

PCT
PCT/US2008/001097
01/28/2008
Methods of Modulating Immune Function
CU1760C- PCT1

United States
12/011,643
01/28/2008
Methods of Modulating Immune Function
CU1760C-US2

United States
12/021'118
01/28/2008
Methods of Modulating Immune Function
CU1760C-US1

United States
61/191,740
09/11/2008
The Immune Response to HIV
CU1760C- PPA3

Country
Serial No
File Date
Title
lnternal ID

United States
61/000,152
10/23/2007
Competitive Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding
CU1969C- PPA1

United States
61/135,942
07/25/2008
Clip Inhibitors and Methods of Modulating Immune Function
CU1969C- PPA2

United States
61/135,964
07/25/2008
Competitive Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding
CU1996C- PPA3

United States
61/137,150
07/25/2008
Methods for Treating Viral Disorders
CU1969C-PPA4

PCT
PCT/US2008/012078
10/23/2008
Competitive Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding
CU1969C-PCT1

United States
15/508,554
07/23/2009
Methods for Treating Viral Disorders
CU1969C- US1

PCT
Pending
7/23/2009
Methods For Treating Viral Disorders
CU1969C-PCT3

PCT
Pending
7/23/2009
Clip Inhibitors and Methods of Modulating Immune Function
CU1969C-PCT2

United States
12/508,543
7/23/2009
Clip Inhibitors and Methods of Modulating Immune Function
CU1969C-US2

United States
61/135,922
7/25/2008
Proteins for Use in Diagnosing and Treating Infection and Disease
CU2421H-PPA1

United States
12/508,532
7/23/2009
Proteins for Use in Diagnosing and Treating Infection and Disease
CU2421H-US1

PCT
Unknown
7/23/2009
Proteins for Use in Diagnosing and Treating Infection and Disease
CU2421H-PCT1

Field of Use

Field of Use means the diagnosis, detection, prevention, and treatment of any disease.

License Grant

University grants to Licensee and its Affiliates under the Licensed Patents an exclusive license to the Licensed Patents, and an exclusive license to the Know How, to make, have made, use, import, offer to sell and sell Licensed Products and to practice the Licensed Process(es) in the Field of Use and Territory.

License Property

Invention Disclosures

10031C –Methods and Uses to Alter Neuronal Stem Cell Fate

10037C — Use of soluble Fas (CD95) in cyanoacrylate to promote wound healing and as a wound sealant (no patents filed under this number)

10038C — Promotion of diabetic wound healing by incorporation of insulin in a cyanoacrylate wound sealant (no patents filed under this number)

10039C — Use of soluble FasL in cyanoacrylate to promote wound healing and as a wound sealant (no patents filed under this number)

10040C –Wound healing promotion by delivery of colloidal silver in a cyanoacrylate wound sealant

2002.012C –Use of Low Frequency Microwave for Repair of Central Nervous System Injury Including Stroke, Trauma, Alzheimers, Parkinson's Disease, Multiple Sclerosis

2002.013C — Use of Low Frequency Microwaves to Alter Plasma Membrane Potential in Cells in Diseases (no patents filed under this number)

2002.014C –Use of Low Frequency/Intensity Microwaves in Combination with Metallic Particles to Enhance the Effect of Microwaves on Electron Transport and Mitochondrial Function (no patents filed under this number)

2002.015C –Use of 2-deoxyglucose to Promote the Effectiveness of Low Frequency/Intensity Microwaves to Alter Mitochondrial Function (no patents filed under this number)

2002.016C –Use of Low Frequency Microwaves to Alter Electron Transport in Mitochondria of Wounds (no patents filed under this number)

2002.017C — Use of Low Intensity Microwaves to Modulate Expression and Transport of Costimulatory Molecules (no patents filed under this number)

2002.018C –Use of Low Frequency/Intensity Microwaves as a Method for the Detection of Breast Cancer Cells (no patents filed under this number)

2002.019C –Use of Low Intensity Microwaves to Treat Type I and Type II Diabetic Neuropathies, Nephropathies, Pathologies of the Eye, Muscle Wasting, and Wound Healing (no patents filed under this number)

2002.020C –Use of Low Frequency Microwaves to Treat Cancers in Concert with Immunological Therapeutics (no patents filed under this number)

2002.021C –Use of Low Frequency Microwaves as a Method of Augmenting Traditional Chemotherapeutic Techniques and/or Traditional Radiation Therapy (no patents filed under this number)

2002.022C –Methods and Uses of Radio Protection Using Small Acidic Spore Protein and Human and Animal Analogs of Small Acidic Spore Protein (no patents filed under this number)

2002.023C — Method of Promoting, Preventing, Sustaining, or Shortening Neural Synapse by Manipulation of Mitochondrial, Liposomal, or Plasma Membrane Uncoupled (no patents filed under this number)

2002.030C –Methods and Products to Lower, Increase, or Remove Cell Surface Costimulatory Molecules by Altering Levels of Intracellular Reactive Oxygen Intermediates (no active patents)

2002.031C –Use of Inhibitors or Promoters of 2, 4 dienoyi-CoA-reductase to Promote or Prevent Reactive Oxygen Production

2002.032C –Use of Inhibitors or Promoters of 2,4 denoyi-CoA-isomerase to Promote or Prevent Reactive Oxygen Production (no patents filed under this number)

2002.033C — Use of Probiotic Delivery of Self Antigens for Immunological therapy in Autoimmune Diseases/Use of Various Strains of Probiotics to Determine Cytokine Bias (no patents filed under this number)

2002.034C — Use of Oral Administration ofT Cell Receptor Peptides Expressed in Probiotic Delivery System to Induce Therapeutic Immune Responses as Indicated (no patents filed under this number)

2002.035C –Use of Ligands for B7.1, B7.2, CD28, or CTLA4 in Cyanoacrylates to Promote Wound Healing (no patents filed under this number)

2002.036C — Use of Microwaves and Cyanoacrylate to Promote Wound Healing (no patents filed under this number)

2002.081C –Methods and Uses to Alter Neuronal Stem Cell Fate by Manipulation of Uncoupling Protein(s)

2002.119C –A Means of Preserving Organs, Tissue, and Stem Cells for Transplant, and for Improving the Success of Transplantation (no patents filed under this number)

CU1008C –Methods for Lowering Costimulatory Molecule Expression on Embryonic Stem Cells through Modulations of Oxidant Levels in the Cell with or without TCR Peptide or Other Peptide Vaccination (no patents filed under this number)

CU1014C –Method to Determine Rates of Cellular Division, Apoptosis, Oncosis or Growth Arrest through Use of Flow Cytometry (no patents filed under this number)

CU1047C –The use of saturated and polyunsaturated fatty acids to promote the effectiveness of gamma interferon as an immunogenic agent (no patents filed under this number)

CU1048C –A Diagnostic Screen of Peripheral Blood as an Indicator of Metabolic Dysfunction and Consequent Altered Immunity Disease (no patents filed under this number)

CU1049C — Use of polyphosphorylated nucleotides to change metabolic base states in cells (no patents filed under this number)

CU1050C –Methods and uses to induce or inhibit translocation of uncoupling proteins to and from cellular sites including plasma membrane organelles (no patents filed under this number)

CU1063C –Use of Fas Engagement and Selective Fatty Acids to Promote or Prevent Cell Viability Through Induction of Active Uncoupling Proteins Activity (no patents filed under this number)

CU1065C — Microinjection of Mitochondria Into Stem Cells, Growing Cells, or Dysfunctional Cells as a Therapeutic Manipulation in Diseases (no patents filed under this number)

CU1081C –Biochemical Process for the Separation of Toxic Substances, Including Heavy Metals Contained in Circuit Boards (no active patents)

CU1098C –A Therapeutic Approach to Pathogenesis of Down Syndrome (no patents filed under this number)

CU1099C –Blood Test for Early Detection of Down Syndrome (no patents filed under this number)

CU1105C — Micro/Nano Devices and Nanoparticles and Implants for Detecting and Altering Cellular and Tissue Metabolism (no patents filed under this number)

CU1125C –Methods and uses to protect or destroy nuclear DNA by manipulations of a newly discovered nuclear membrane uncoupling protein (UCP) or uncoupling-like protein/molecule (no patents filed under this number)

CU1128C –NUCLEI Methods and Uses to Protect or Destroy Nuclear DNA by Manipulations of a Newly Discovered Nuclear Membrane Uncoupling Protein (UCP) or Uncoupling-Like Protein Molecule (no patents filed under this number)

CU1138C — Novel Therapies for Tissue Repair, Remodeling, Reconstruction and Regeneration

CU1244C –Methods and Uses to Kill Tumor Cells In Vivo Using a Toxin Derived from the Black Widow Spider, Latrotoxin (no patents filed under this number)

CU1245C –The Use of Genistein to Supplement the Activity of Chemotherapeutic and Metabolic Modifying Agents (no patents filed under this number)

CU1246C –Use of Myxococcus Xanthus to Eliminate the Environmental Toxicity of Methane Production by Methanobacteria (no patents filed under this number)

CU1248C –Computer Software for Improved Flow Cytometric Data Analysis (no active patents)

CU1249C — Cybenetic Biovitiation (no patents filed under this number) CU1344C –Array for Metabolic Analysis (no active patents)

CU1518C — Myxococcus xanthus derived oncolytic agent (no patents filed under this number)

CU1696H –Induction of apoptosis in tumor cells (no patents filed under this number)

CU1715C –Metabolic Modifications in Plants as a Mechanism for Increasing Plant derived Ethanol or Oil for Fuel Production

CU1968C –Inhibition of Fatty Acid Oxidation (FAO) to potentiate drug sensitivity in breast cancer

CU2407H –Systems and Methods for Treating Human Inflammatory and Proliferative Diseases and Wounds, with a Combination of Chloroquine and a Glycolytic Inhibitor

CU2421H –Proteins for Use in Diagnosing and Treating Infection and Disease

License Grant

The Licensor grants Licensee an exclusive License under Patent Rights to make, have made, use and sell the Licensed Products in all Fields of Use, in the worldwide territory, and to grant sub-Licenses of the same scope, to the end of the term of this Agreement. This Agreement, unless sooner terminated will remain in effect until expiration or the last to expire patent under Patent Rights.

License Property

MHC Engagement and CLIP Modulation for the treatment of Disease.

CLIP Modulation for the treatment of mucosal disease.

Cancer biomarkers and therapies.

Methods and products for treating pre-eclampsia and modulating Blood Pressure.

and any know-how and materials disclosed to Parties by Dr. Newell between March 20, 2010 and the Effective Date regarding the Patent Rights.

Field of Use

The Licensee discovers and develops drug therapies to treat infectious, autoimmune, and immunological deficiency disorders using its thymus nuclear protein compound (TNP). Targeted Peptides and Metabolic Disruption and is researching the use of these technologies in the treatment of cancer, infectious disease, and inflammation.

License Grant

A University hereby grants to the Licensee an exclusive License under Patent Rights, including the right to grant sublicenses.

License Property

The licensed field is for the diagnosis, treatment and prevention of autoimmune disease and includes inventions disclosed in Disclosure Docket No. SD1993-268  â€œMethod and Reagents for the Treatment of Rheumatoid Arthritis'/ 'Vaccine Compositions and Methods Useful in Inducing Immune Protection Against Arthritogenic Peptides Involved in the Pathogenesis of Rheumatoid Arthritis'; SD2000-133, 'Pan HLA DR Binding Heat Shock Protein Peptides as Immunomodulatory Tools'; SD2001-901, 'Pan HLA DR Binding Heat Shock Proteins as Immunomodulatory Tools'; SD2002-051 'Methods of Epitope-Specific and Cytokine/Anticytokine Immunotherapy for Modulation of Pathogenic Immune Responses in Mediated Diseases'; and SD2006-256 'Methods and Formulations for Epitope Specific Immunotherapy.'

Field of Use

'Field' means diagnosis, treatment and prevention of autoimmune disease.